Red Door Communications has been appointed by Sweden-headquartered Meda Pharmaceuticals to handle PR for two of its oral hygiene brands.
The two separate briefs include helping to revitalise the sore throat brand Difflam and to launch Meda’s new breath freshener CB12.
Diffram, which combines anti-inflammatory, analgesic and anaesthetic ingredients, is an established sore throat treatment, which the agency plans to promote through a combination of on- and offline activity.
“We are looking forward to generating some real talk-ability around Difflam, as we move towards the key sore throat season later this year, with a creative and high profile campaign focused on those groups of consumers most impacted by the debilitating effects of a sore throat,” said Julia Harries, director and head of consumer health at Red Door Communications.
CB12 will be launched in the UK later this year, having already appeared in other markets around Europe.
Meda Pharmaceuticals’ Neil Lawrence said: “There has been a huge demand for CB12 in the markets where it has launched to date, driven by its unique, clear brand promise, unique patented formula and demonstrable 12-hour ‘safe breath’ consumer offer.
“We’re looking forward to replicating that success in the UK when CB12 launches later this year.”
Harries added: “CB12 has a wealth of supporting evidence and a compelling clinical story to tell. We are looking forward to taking that message out to both consumer and healthcare professional audiences via a combination of on and offline channels including media outreach and experiential communications.”